tiprankstipranks
Trending News
More News >

Personalis’ NeXT Personal predicts cervical cancer recurrence risk

Personalis (PSNL) announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology 2025 Annual Meeting in Chicago in an oral presentation titled “Ultrasensitive detection and tracking of circulating tumor DNA and association with relapse and survival in locally advanced cervical cancer”: Phase 3 CALLA trial analyses.” The results from this study were also simultaneously published in the journal Annals of Oncology.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue